according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 2.6
 09.04.2021
 1567799-00009
 Date of first issue: 18.04.2017

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Ezetimibe Granules Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Pharmaceutical

stance/Mixture

1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.

30 Hudson Street, 33nd floor

07302 Jersey City, New Jersey, U.S.A

Telephone : 551-430-6000

E-mail address of person responsible for the SDS

EHSSTEWARD@organon.com

1.4 Emergency telephone number

215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Long-term (chronic) aquatic hazard, Category 2 H411: Toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :

Hazard statements : H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P273 Avoid release to the environment.

Response:

P391 Collect spillage.

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 2.6 09.04.2021 1567799-00009 Date of first issue: 18.04.2017

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Ezetimibe	163222-33-1	Aquatic Chronic 1; H410 M-Factor (Chronic aquatic toxicity): 1	>= 2,5 - < 10
Sodium n-dodecyl sulfate	151-21-3 205-788-1	Acute Tox. 4; H302 Skin Irrit. 2; H315 Eye Dam. 1; H318 Aquatic Chronic 3; H412 specific concentra- tion limit Eye Irrit. 2; H319 10 - < 20 % Eye Dam. 1; H318 >= 20 %	>= 1 - < 2,5

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 2.6 09.04.2021 1567799-00009 Date of first issue: 18.04.2017

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with plenty of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Nitrogen oxides (NOx)
Fluorine compounds
Sulphur oxides
Metal oxides

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 2.6
 09.04.2021
 1567799-00009
 Date of first issue: 18.04.2017

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 2.6
 09.04.2021
 1567799-00009
 Date of first issue: 18.04.2017

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust. Do not swallow.

Avoid contact with eyes.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store in accordance with

the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form	Control parameters	Basis
		of exposure)		
Ezetimibe	163222-33- 1	TWA	25 μg/m3 (OEB 3)	Internal
		Wipe limit	250 μg/100 cm ²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
Sodium n-dodecyl sulfate	Workers	Inhalation	Long-term systemic effects	285 mg/m3
	Workers	Skin contact	Long-term systemic effects	4060 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	85 mg/m3
	Consumers	Skin contact	Long-term systemic effects	2440 mg/kg bw/day

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 2.6
 09.04.2021
 1567799-00009
 Date of first issue: 18.04.2017

Consumers Ingestion Long-term systemic 24 mg/kg effects bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Sodium n-dodecyl sulfate	Fresh water	0,176 mg/l
	Marine water	0,018 mg/l
	Sewage treatment plant	1,35 mg/l
	Fresh water sediment	6,97 mg/kg dry weight (d.w.)
	Marine sediment	0,697 mg/kg dry weight (d.w.)
	Soil	1,29 mg/kg dry weight (d.w.)

8.2 Exposure controls

Engineering measures

Ensure adequate ventilation, especially in confined areas.

Minimize workplace exposure concentrations.

Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

Eye protection : Wear the following personal protective equipment:

Safety goggles

Equipment should conform to NS EN 166

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending

on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the

end of workday.

Skin and body protection : Skin should be washed after contact.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Equipment should conform to NS EN 143

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : granular Colour : white

Odour : No data available

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

Version SDS Number: Date of last issue: 10.10.2020 Revision Date: Date of first issue: 18.04.2017 2.6 09.04.2021 1567799-00009

Odour Threshold No data available

Melting point/freezing point No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point Not applicable

Auto-ignition temperature No data available

Decomposition temperature

Decomposition tempera-

ture

No data available

pΗ No data available

Viscosity

Viscosity, kinematic No data available

Solubility(ies)

Water solubility No data available

Partition coefficient: n-

octanol/water

No data available

Vapour pressure

No data available

No data available Density

Relative vapour density No data available

Particle characteristics

Particle size No data available

9.2 Other information

Explosives Not explosive

Oxidizing properties The substance or mixture is not classified as oxidizing.

Evaporation rate No data available

Molecular weight No data available

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 2.6
 09.04.2021
 1567799-00009
 Date of first issue: 18.04.2017

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

exposure Skin contact

Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg

Method: Calculation method

Components:

Ezetimibe:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

LD50 (Mouse): > 5.000 mg/kg

LD50 (Dog): > 3.000 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 2.6 09.04.2021 1567799-00009 Date of first issue: 18.04.2017

Acute toxicity (other routes of :

administration)

LD50 (Rat): > 2.000 mg/kg

Application Route: Intraperitoneal

LD50 (Mouse): > 1.000 - < 2.000 mg/kg Application Route: Intraperitoneal

Sodium n-dodecyl sulfate:

Acute oral toxicity : LD50 (Rat): 1.200 mg/kg

Method: OECD Test Guideline 401

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg

Method: OECD Test Guideline 402

Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:

Ezetimibe:

Species : Rabbit

Result : No skin irritation

Sodium n-dodecyl sulfate:

Species : Rabbit Result : Skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Ezetimibe:

Species : Rabbit

Result : No eye irritation

Sodium n-dodecyl sulfate:

Species : Rabbit

Method : OECD Test Guideline 405
Result : Irreversible effects on the eye

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 2.6 09.04.2021 1567799-00009 Date of first issue: 18.04.2017

Components:

Ezetimibe:

Test Type : Maximisation Test

Species : Guinea pig Result : negative

Sodium n-dodecyl sulfate:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:

Ezetimibe:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Metabolic activation: with and without metabolic activation

Result: negative

Test Type: Chromosomal aberration Test system: Human lymphocytes

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse

Cell type: Bone marrow Application Route: Oral Result: negative

Nesult negativ

Sodium n-dodecyl sulfate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Rodent dominant lethal test (germ cell) (in vivo)

Species: Mouse

Application Route: Ingestion

Result: negative

Carcinogenicity

Not classified based on available information.

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 2.6 09.04.2021 1567799-00009 Date of first issue: 18.04.2017

Components:

Ezetimibe:

Species : Rat, female
Application Route : oral (feed)
Exposure time : 104 weeks
Result : negative

Species : Rat, male
Application Route : oral (feed)
Exposure time : 104 weeks
Result : negative

Species : Mouse
Application Route : oral (feed)
Exposure time : 104 weeks
Result : negative

Sodium n-dodecyl sulfate:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years

Method : OECD Test Guideline 453

Result : negative

Remarks : Based on data from similar materials

Reproductive toxicity

Not classified based on available information.

Components:

Ezetimibe:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat, male and female

Fertility: NOAEL: > 1.000 mg/kg body weight Result: No effects on fertility, No fetotoxicity

Effects on foetal develop-

ment

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: > 1.000 mg/kg body weight

Result: No adverse effects

Test Type: Development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: > 1.000 mg/kg body weight

Result: No adverse effects

Sodium n-dodecyl sulfate:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 2.6
 09.04.2021
 1567799-00009
 Date of first issue: 18.04.2017

Application Route: Ingestion Method: OECD Test Guideline 416

Result: negative

Remarks: Based on data from similar materials

Effects on foetal develop-

ment

Test Type: Embryo-foetal development Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Ezetimibe:

Species : Dog

NOAEL : 1.000 mg/kg

Application Route : Oral Exposure time : 90 d

Remarks : No significant adverse effects were reported

Species : Rat

NOAEL : 1.500 mg/kg

Application Route : Oral Exposure time : 90 d

Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 90 d

Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 300 mg/kg
Application Route : Oral
Exposure time : 1 yr

Remarks : No significant adverse effects were reported

Sodium n-dodecyl sulfate:

Species : Rat
NOAEL : 488 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Remarks : Based on data from similar materials

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 2.6
 09.04.2021
 1567799-00009
 Date of first issue: 18.04.2017

Aspiration toxicity

Not classified based on available information.

Components:

Ezetimibe:

Not applicable

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

Experience with human exposure

Components:

Ezetimibe:

Ingestion : Symptoms: Headache, Nausea, Vomiting, Diarrhoea, flatu-

lence, muscle pain, upper respiratory tract infection, Back

pain, joint pain

SECTION 12: Ecological information

12.1 Toxicity

Components:

Ezetimibe:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 0,125 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 4 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): >

0,317 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 0,317

mg/l

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 2.6
 09.04.2021
 1567799-00009
 Date of first issue: 18.04.2017

Exposure time: 96 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 4,4 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

NOEC: 4,4 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

icity)

NOEC: 0,051 mg/l Exposure time: 33 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

NOEC: 4 mg/l Exposure time: 7 d

Species: Cyprinodon variegatus (sheepshead minnow)

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0,282 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic

toxicity)

1

Sodium n-dodecyl sulfate:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 29 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Ceriodaphnia dubia (water flea)): 5,55 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

ErC50 (Desmodesmus subspicatus (green algae)): > 120 mg/l

Exposure time: 72 h

NOEC (Desmodesmus subspicatus (green algae)): 30 mg/l

Exposure time: 72 h

Toxicity to microorganisms : EC50 : 135 mg/l

Exposure time: 3 h

Toxicity to fish (Chronic tox-

icity)

NOEC: >= 1,357 mg/l

Exposure time: 42 d

Species: Pimephales promelas (fathead minnow)

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 2.6
 09.04.2021
 1567799-00009
 Date of first issue: 18.04.2017

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0,88 mg/l Exposure time: 7 d

Species: Ceriodaphnia dubia (water flea)

12.2 Persistence and degradability

Components:

Ezetimibe:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 6,8 % Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(4,5 d)

Method: OECD Test Guideline 111

Sodium n-dodecyl sulfate:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 95 % Exposure time: 28 d

Method: OECD Test Guideline 301B

12.3 Bioaccumulative potential

Components:

Ezetimibe:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)

Exposure time: 97 d

Bioconcentration factor (BCF): 173 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

log Pow: 4,36

Sodium n-dodecyl sulfate:

Partition coefficient: n-

octanol/water

log Pow: 0,83

12.4 Mobility in soil

Components:

Ezetimibe:

Distribution among environ-

- : log Koc: 4,35

mental compartments Method: OECD Test Guideline 106

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 2.6 09.04.2021 1567799-00009 Date of first issue: 18.04.2017

0.1% or higher.

12.6 Other adverse effects

Product:

Endocrine disrupting poten-

tial

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation

(EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : UN 3077
ADR : UN 3077
RID : UN 3077
IMDG : UN 3077
IATA : UN 3077

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Ezetimibe)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Ezetimibe)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Ezetimibe)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Ezetimibe)

IATA : Environmentally hazardous substance, solid, n.o.s.

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 2.6 09.04.2021 1567799-00009 Date of first issue: 18.04.2017

(Ezetimibe)

14.3 Transport hazard class(es)

 ADN
 : 9

 ADR
 : 9

 RID
 : 9

 IMDG
 : 9

 IATA
 : 9

14.4 Packing group

ADN

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

ADR

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

IMDG

Packing group : III Labels : 9

EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo : 956

aircraft)

Packing instruction (LQ) : Y956 Packing group : III

Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passen: 956

ger aircraft)

Packing instruction (LQ) : Y956
Packing group : III

Labels : Miscellaneous

14.5 Environmental hazards

ADN

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 2.6 09.04.2021 1567799-00009 Date of first issue: 18.04.2017

RID

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on : Not applicable

the market and use of certain dangerous substances,

preparations and articles (Annex XVII)

REACH - Candidate List of Substances of Very High : Not applicable

Concern for Authorisation (Article 59).

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

Regulation (EC) No 1005/2009 on substances that de: Not applicable

plete the ozone layer

Regulation (EU) 2019/1021 on persistent organic pollu- : Not applicable

tants (recast)

Regulation (EC) No 649/2012 of the European Parlia: Not applicable

ment and the Council concerning the export and import

of dangerous chemicals

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Quantity 1 Quantity 2 ENVIRONMENTAL 200 t 500 t

HAZARDS

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 2.6
 09.04.2021
 1567799-00009
 Date of first issue: 18.04.2017

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H302 : Harmful if swallowed. H315 : Causes skin irritation.

H318 : Causes serious eye damage.

H410 : Very toxic to aquatic life with long lasting effects.H412 : Harmful to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Chronic : Long-term (chronic) aquatic hazard

Eye Dam. : Serious eye damage

Skin Irrit. : Skin irritation

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN -Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS -Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP -Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA -Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 2.6
 09.04.2021
 1567799-00009
 Date of first issue: 18.04.2017

Sources of key data used to compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Classification of the mixture: Classification procedure:

Aquatic Chronic 2 H411 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN